BioCentury
ARTICLE | Translation in Brief

Biogen buddies up

Biogen joins consortia for ALS and target validation

March 24, 2016 7:00 AM UTC

While some players are starting to talk of "consortia fatigue," Biogen Inc. (NASDAQ:BIIB) is doubling down on its enthusiasm for the model with two new commitments to multilateral public-private partnerships (PPPs).

On February 8, the company announced it was joining the Centre for Therapeutic Target Validation (CTTV), a two-year old partnership between GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust's Sanger Institute. ...